Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination Strategies
Ida Aronchik(Revolution Medicines (United States)), Mallika Singh(Revolution Medicines (United States)), Minal Barve(Mary Crowley Cancer Research Center), Lo Lai(Georgia State University), Matthew Holderfield(Revolution Medicines (United States)), Elsa Quintana(Revolution Medicines (United States)), Brian Wolpin(Dana-Farber Cancer Institute), David S. Hong(The University of Texas MD Anderson Cancer Center), Jacqueline A.M. Smith(Revolution Medicines (United States)), Sumit Kar(Revolution Medicines (United States)), Kevin Yang(Revolution Medicines (United States)), James Evans(Temple College), Ignacio Garrido‐Laguna(University of Utah), Julien Dilly(Massachusetts Institute of Technology), Wungki Park(University of Miami), Kyle J. Seamon(Revolution Medicines (United States)), Aparna Hegde(University of Colorado Cancer Center), Alexander I. Spira(Virginia Cancer Specialists), Brett Garrick(Revolution Medicines (United States)), Anirban Maitra(NYU Langone Health), Harika Gundlapalli(Revolution Medicines (United States)), Ashenafi Bulle(KU Leuven), Jason K. Yano(Fleet Science Center), Clay Gustafson(Revolution Medicines (United States)), Vidya Devanathadesikan Seshadri(Revolution Medicines (United States)), David Sommerhalder(Texas Oncology), Salman R. Punekar(NYU Langone Health), Mark P. Labrecque(Revolution Medicines (United States)), Kevin Lin(The University of Texas MD Anderson Cancer Center), Cristina Blaj(Revolution Medicines (United States)), Andrew J. Aguirre(Broad Institute), Biswadeep Nayak(Revolution Medicines (United States)), Kian‐Huat Lim(Washington University in St. Louis), Brad Sickler(Revolution Medicines (United States)), Yevgeniy Gindin(Revolution Medicines (United States)), Ethan Ahler(Revolution Medicines (United States)), Lingyan Jiang(Revolution Medicines (United States)), Yongxian Zhuang(Mayo Clinic), Meredith Pelster(Mary Crowley Cancer Research Center), Ciara Helland(Revolution Medicines (United States)), Jingjing Jiang(Revolution Medicines (United States)), Steve Kelsey(Revolution Medicines (United States)), Alexander Starodub(Dana-Farber Cancer Institute), Sean Bredeson(Revolution Medicines (United States)), Marie Ménard(University of California, San Francisco), Urszula N. Wasko-Kornberg(Revolution Medicines (United States)), Zeena Salman(Revolution Medicines (United States))
Cited by 1
Related Papers
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
|Science|2008|4k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k